- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05816590
Meds@HOME App to Support Medication Safety
Meds@HOME - Improving Medication Safety for Medically Complex Children With mHealth Across Caregiving Networks (R18 Aim 2)
Study Overview
Status
Intervention / Treatment
Detailed Description
The investigators will test the hypothesis that Meds@HOME use improves medication administration accuracy for caregivers by conducting a 6-month randomized controlled trial with caregivers of CMC.
The study population will consist of 1) CMC who are prescribed at least one scheduled high-risk medication and receive care at UW Health, and 2) their caregivers. The study distinguishes between three types of caregivers: 1) primary caregivers (child's parent or legal guardian), 2) secondary caregivers (up to 2 individuals who regularly provide care for the child and who complete study surveys), and 3) other caregivers (invited to use the app but not complete study surveys). CMC and their primary caregiver participants will be randomized into intervention (Meds@HOME, "I") or control ("C") groups. Assessments at baseline and 6 months post-enrollment will assess the primary endpoint (medication administration accuracy), secondary outcomes, and Meds@HOME use by primary and secondary caregivers.
Participant accrual will occur over 12 months at one site and participants can expect to be on study for 6 months.
The primary study objective is to evaluate the effectiveness of Meds@HOME on primary caregiver medication administration accuracy.
The secondary objectives are to evaluate Meds@HOME's:
- effectiveness on secondary caregiver medication administration accuracy
- effect on adverse drug event (ADE) hospital use
- effect on adverse drug event ED use
- effect on parent-reported medication adherence
- effect on parent-reported medication activation
- effect on parent-reported medication confidence
- effect on parent-reported medication understanding
- effect on all-cause hospital use
- effect on all-cause ED use
- effect on mortality
- effect on the primary outcome measured as 5 individual components
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Gemma Warner
- Phone Number: (608) 263-0740
- Email: gwarner@pediatrics.wisc.edu
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Recruiting
- University of Wisconsin-Madison, UW Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria (Child with Medical Complexity):
- less than or equal to 17 years of age at start of study
- In the last 12 months, child has had at least two or more encounters (in-person or telehealth clinic visit, ED visit, or hospital admission) in the UWHC/AFCH system
- Child has 2 or more different complex chronic conditions
- Child has at least 1 active, outpatient prescription for a scheduled high-risk medication
- Provided assent, if appropriate
Inclusion Criteria (Primary Caregiver):
- Provided written informed consent form as the child's parent or legal guardian
- Willing to comply with all study procedures and available for the duration of the study
- At least 18 years of age
- Comfortable speaking and reading in English
- Self-identifies as a primary caregiver of a study-eligible CMC
- Currently provides care on an ongoing basis to the study-eligible CMC. Child may not be housed in a skilled nursing facility, an acute care or transitional facility, a rehabilitative hospital, or in a medical group home
- Has iOS or Android mobile device (smartphone, tablet) with a phone plan that includes daily Wi-Fi service and data
Inclusion Criteria (Secondary Caregiver):
- Has been identified as a "secondary caregiver" by the primary caregiver
- Provided informed consent
- Willing to comply with all study procedures and be available for the duration of the study
- At least 18 years of age
- Comfortable speaking and reading in English
- Currently provides care on an ongoing basis to the study-eligible CMC
- Administers medications to the study-eligible CMC
- Has an iOS or Android mobile device (smartphone) with a phone plan that includes daily Wi-Fi service and data
Inclusion Criteria (Other Caregivers - Treatment Group only):
- Has been identified by a primary caregiver assigned to the intervention group as a person providing care to the child
- Has been invited by the primary caregiver to use the app (i.e., sent email invitation via Meds@HOMEapp)
- Signed up to become a Meds@HOME user by clicking on link in email invitation and completing user registration
- Is not participating in study survey data collection as a secondary caregiver
Exclusion Criteria:
- Failure to meet all inclusion criteria
- Another child from the household is already enrolled in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control Group
|
|
Experimental: Meds@HOME Intervention
|
Meds@HOME is a software application designed for use on a personal mobile device.
The app allows primary caregiver to create routines where they can detail how to perform the routine, start date and time, and frequency (daily, weekly, monthly).
Optional push notifications can be set so that users are alerted to an upcoming routine.
Only primary caregivers can create, edit, and delete routines.
All caregivers can check off on routines and receive notifications.
Caregivers can also post notes related to routines or events.
App enables an inventory of caregiver troubleshooting strategies and inventory reminders.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Percentage of Participants Demonstrating Medication Administration Accuracy
Time Frame: baseline (before randomization), 6 months
|
Rate of medication administration accuracy, measured dichotomously as correct identification of each of the following for a randomly selected high risk medication: indication, formulation, dose, frequency, and route after 6-months
|
baseline (before randomization), 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Percentage of Participants Demonstrating Medication Administration Accuracy among Secondary Caregivers
Time Frame: baseline (before randomization), 6 months
|
Rate of medication administration accuracy, measured as in the primary outcome, amongst secondary caregivers after 6-months
|
baseline (before randomization), 6 months
|
Count of University of Wisconsin (UW) hospital encounters during study period with Adverse Drug Event (ADE) codes
Time Frame: up to 6 months
|
up to 6 months
|
|
Count of UW Emergency Department (ED) encounters during study period with ADE codes
Time Frame: up to 6 months
|
up to 6 months
|
|
Mean parent-reported medication adherence using the Adherence to Refills and Medications Scale (ARMS)
Time Frame: up to 6 months
|
ARMS is a 12-item instrument scored from 12 to 34, with lower scores indicating better adherence.
|
up to 6 months
|
Mean FCAT (Family Caregiver Activation in Transition) Score for 5 medication-specific items
Time Frame: up to 6 months
|
FCAT Score for 5 medication-specific items - composite and individual items will be reported after 6-months.
Scoring is from 1-5 with higher scores indicating fewer challenges to care.
|
up to 6 months
|
Parent-Reported Medication Confidence
Time Frame: up to 6 months
|
To evaluate Meds@HOME's effect on parent-reported medication confidence.
Mean composite score after 6-months.
Medication Confidence is measured on a 7-item survey scored on a 5 point likert scale for a total possible range of scores from 7-35 where lower scores indicate increased medication confidence.
|
up to 6 months
|
Parent-Reported Medication Understanding
Time Frame: up to 6 months
|
To evaluate Meds@HOME's effect on parent-reported medication understanding.
Mean composite score after 6-months.
Medication Understanding is measured on a 5-item survey scored on a 5 point likert scale for a total possible range of scores from 5-25 where lower scores indicate increased medication understanding.
|
up to 6 months
|
Count of hospital encounters and hospital days during study period
Time Frame: up to 6 months
|
Count of hospital encounters and hospital days during study period.
|
up to 6 months
|
Count of ED encounters during study period
Time Frame: up to 6 months
|
Count of ED encounters during study period.
|
up to 6 months
|
Count of deaths during the study period
Time Frame: up to 6 months
|
Count of deaths during the study period
|
up to 6 months
|
Rate of Medication Adherence for Individual Components (indication, formulation, dose, frequency, and route)
Time Frame: up to 6 months
|
Rate of individual components each measured dichotomously (indication, formulation, dose, frequency, and route).
|
up to 6 months
|
Mean Number of Individual Components of Medication Adherence Correct
Time Frame: up to 6 months
|
Mean number of individual components correct (from 0 components to all 5: indication, formulation, dose, frequency, route).
|
up to 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ryan Coller, MD, MPH, University of Wisconsin, Madison
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2022-1620
- A536771 (Other Identifier: UW Madison)
- Protocol Version 2/7/23 (Other Identifier: UW Madison)
- Pediatric Hospitalist (Other Identifier: UW Madison)
- R18HS028409 (U.S. AHRQ Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medication Errors and Other Product Use Errors and Issues
-
National Institute of Cardiovascular Diseases,...CompletedMedication Errors and Other Product Use Errors and IssuesSlovakia
-
Universidad Miguel Hernandez de ElcheEnrolling by invitationMedication Errors and Other Product Use Errors and IssuesSpain
-
Fundación para el Fomento de la Investigación Sanitaria...Enrolling by invitationMedication Errors and Other Product Use Errors and IssuesSpain
-
Fundación para el Fomento de la Investigación Sanitaria...RecruitingMedication Errors and Other Product Use Errors and Issues | CaringSpain
-
Hospital de GranollersCompletedMedication Adherence | Medication Errors and Other Product Use Errors and Issues | Antibiotic Resistance, MicrobialSpain
-
Fondazione Poliambulanza Istituto OspedalieroUnknownMedication Errors and Other Product Use Errors and Issues | Adverse Drug EventItaly
-
Columbia UniversityTerminatedMedication Errors | Medication AdministrationUnited States
-
Juul Labs, Inc.CelerionCompletedTobacco Use | Smoking, Tobacco | Nicotine Dependence, Other Tobacco ProductUnited States
-
Juul Labs, Inc.Rose Research Center, LLCCompletedTobacco Use | Tobacco Smoking | Nicotine Dependence, Other Tobacco ProductUnited States
-
Yale UniversityCompletedNicotine Dependence, Other Tobacco ProductUnited States
Clinical Trials on Med@HOME Mobile App
-
Hospital Authority, Hong KongThe Hong Kong Polytechnic UniversityUnknownHip Fractures | RehabilitationHong Kong
-
The University of Hong KongNorth District Hospital; Queen Mary Hospital, Hong Kong; Pamela Youde Nethersole... and other collaboratorsUnknownSelf Inflicted Injury | Suicide and Self Inflicted InjuryHong Kong
-
University of ValenciaMinistry of Science and InnovationNot yet recruiting
-
University of California, San FranciscoSan Francisco Veterans Affairs Medical CenterRecruitingPost Traumatic Stress DisorderUnited States
-
Duke UniversityDuke Institute for Health InnovationCompleted
-
Weill Medical College of Cornell UniversityChildren's Health FundNot yet recruitingDepression | Bipolar Disorder | Anxiety Disorders and Symptoms | SymptomsUnited States
-
University of ZurichSwitzerland: ETH; Switzerland: MakoraCompleted
-
Ksana HealthNovo Nordisk A/SCompletedObesity | Overweight | Mental Health DisorderUnited States
-
Arizona State UniversityThe University of Texas Health Science Center at San AntonioCompleted
-
Butler HospitalNational Institute of Mental Health (NIMH)Completed